1391918-17-4 Usage
Description
C20H23FN6O6, also known as Raltegravir, is a potent human immunodeficiency virus (HIV) integrase inhibitor. It is an anti-AIDS drug that works by inhibiting the integration of the viral DNA into the host's DNA, thus preventing the replication of the virus. Raltegravir is characterized by its molecular structure containing 20 carbon, 23 hydrogen, 6 fluorine, 6 nitrogen, and 6 oxygen atoms.
Uses
Used in Pharmaceutical Industry:
C20H23FN6O6 is used as an antiretroviral agent for the treatment of HIV-1 infection. It is particularly effective in inhibiting the integration of the viral DNA into the host's DNA, which is a crucial step in the replication of the virus. Raltegravir has demonstrated high efficacy and favorable safety profile in clinical trials, making it a valuable addition to the arsenal of antiretroviral drugs.
Used in HIV Treatment:
C20H23FN6O6 is used as a component of combination antiretroviral therapy (cART) for the treatment of HIV-1 infection. It is often prescribed alongside other antiretroviral drugs to enhance the treatment's effectiveness and reduce the likelihood of the virus developing resistance to the medication.
Used in Research and Development:
C20H23FN6O6 is also used in the research and development of new antiretroviral drugs and therapies. Its molecular structure and mechanism of action provide valuable insights into the development of novel compounds that can target the HIV virus more effectively and with fewer side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 1391918-17-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,9,1,9,1 and 8 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1391918-17:
(9*1)+(8*3)+(7*9)+(6*1)+(5*9)+(4*1)+(3*8)+(2*1)+(1*7)=184
184 % 10 = 4
So 1391918-17-4 is a valid CAS Registry Number.
1391918-17-4Relevant articles and documents
Identification, synthesis, and strategy for minimization of potential impurities observed in raltegravir potassium drug substance
Patil, Gulabrao D.,Kshirsagar, Siddheshwar W.,Shinde, Shivnath B.,Patil, Pankaj S.,Deshpande, Mangesh S.,Chaudhari, Ashok T.,Sonawane, Swapnil P.,Maikap, Golak C.,Gurjar, Mukund K.
, p. 1422 - 1429 (2012/10/29)
Multiple sources of anticipated degradation and process impurities of raltegravir potassium drug substance observed during the laboratory optimization and later during its bulk synthesis are described in this article. The impurities were monitored by UPLC, and their structures are tentatively assigned on the basis of fragmentation patterns in LC-MS and NMR spectroscopy. Most of the impurities are synthesized, and their assigned constitutions were confirmed by co-injection in UPLC. In addition to the formation, synthesis, and characterization, strategy for minimizing these impurities to the level accepted by ICH is also described. We feel that our study will be helpful to the generic industry for obtaining chemically pure raltegravir potassium.
